As of Q4'25, Pfizer's latest EPS Surprise % stands at 0.16%, indicating a modest positive deviation from analyst expectations for the quarter ending December 31, 2025. The most recent YoY EPS Growth for the same period is -5.14%, reflecting a significant decline compared to the previous year. Looking at the period from Q1'23 to Q4'25, the EPS Surprise % has shown considerable volatility, with notable negative surprises in Q3'23 (-0.47%) and Q4'23 (-1.53%), followed by a recovery into positive territory throughout 2024 and 2025. EPS Growth (YoY) was persistently negative through 2023 and early 2024, except for sharp rebounds in Q3'24 (2.88%) and Q4'24 (1.12%), and an exceptional spike in Q2'25 (50%), before dropping sharply to -5.14% in Q4'25. This pattern highlights a period of significant earnings volatility, with occasional strong rebounds but an overall trend of fluctuating performance.